Consumption of ultra-processed foods and incidence of dyslipidemias: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) | British Journal of Nutrition | Cambridge Core
HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button. Ultra-processed foods (UPF)...
Conclusion: Our findings showed important cardiovascular risk associated with consumption of UPF and a gradient in the consumption´s effect, so these products should be discouraged.
Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway
Source : https://www.tandfonline.com/doi/abs/10.1080/08916934.2022.2051142?journalCode=iaut20
Abstract Proprotein convertase subtilisin kexin type 9 (PCSK9) is a well-known proprotein convertase that influences foam cell formation and modulates atherosclerosis. Inclisiran is a novel chemosynthetic small interfering RNA that...
/>
Conclusion: These data suggested that inclisiran inhibited the formation of macrophage-derived foam cells by activating the PPARγ pathway.
Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35279835/
Inclisiran increases the number of low-density lipoprotein surface receptors expressed on hepatocytes using small interfering RNA directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. This novel mechanism can reduce...
Conclusion/Relevance: Thus, inclisirin is a novel small interfering RNA molecule that provides further options in the management of hypercholesterolemia refractory to statins alone. However, cost and evidence considerations suggest it should not supplant adjunctive therapy with the PCSK9-inhibiting monoclonal antibodies, despite having an...
siRNA drug Leqvio (inclisiran) to lower cholesterol
STRUCTURE: Inclisiran is a synthetic, chemically modified, double-stranded siRNA. The sense strand is conjugated with a triantennary N-acetylgalactosamine (GalNAc) ligand to enable targeting of hepatocytes via the asialoglycoprotein receptor (ASGPR)....
/>
Relevance: Inclisiran is indicated as an adjunct treatment along with statin therapy for patients with heterozygous familial hypercholesteremia and atherosclerotic cardiovascular disease , who require additional lowering of LDL-C. It is particularly useful for patients with uncontrolled cholesterol levels even after maximal stain therapies....